Market Overview

UPDATE: Microsoft Downgraded at Bank of America on Lack of Momentum

Share:
UPDATE: Microsoft Downgraded at Bank of America on Lack of Momentum

In a report published by Bank of America, analyst Kash Ragan downgraded Microsoft (NASDAQ: MSFT) from Buy to Neutral and lowered the price objective from $35 to $33.

In the report, Bank of America noted, "Our Buy thesis was predicated on an aggressive $40bn share buyback program and the Win 7 product cycle. We were hoping that MSFT would make a bold foray with Win 8 into smartphones and tablets. Conventional product cycle wisdom dictates that the stock should peak before a Win launch (it hit $31.45 in Sept '12 before Win 8), but we remained optimistic because the limited availability of touch-based devices impaired an objective assessment of Win 8. Now, six months post launch, despite more available touch-based devices, Win 8 lacks momentum, challenging our optimism."

Bank of America held a Buy rating on Microsoft since September 2008. Shares of Microsoft closed Wednesday at $28.56.

Latest Ratings for MSFT

DateFirmActionFromTo
Oct 2019AssumesOutperform
Oct 2019UpgradesHoldBuy
Jul 2019MaintainsOutperform

View More Analyst Ratings for MSFT
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Downgrades Analyst Ratings Best of Benzinga

 

Related Articles (MSFT)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ELMDDougherty & Co.Initiates Coverage On12.0
MRNSCantor FitzgeraldAssumes7.0
MNRLCapital One FinancialInitiates Coverage On23.0
SONVertical GroupUpgrades
UNPMorgan StanleyMaintains136.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Brent Under Pressure From Poor Global Demand

VolitionRx Files Patent Applications for Nucleosomics